Skip to main content
. 2022 Oct 28;13:20406207221132346. doi: 10.1177/20406207221132346

Figure 4.

Figure 4.

Optimization of AML ELN-2017 risk stratification based on ICAM2 expression. (a–c) High expression of ICAM2 is associated with poor prognosis in the intermediate-risk AML and combined with ICAM2 expression improved ELN2017 risk stratification into two groups. (d–f) The possibility and accuracy of ICAM2 to optimize ELN-2017 risk stratification was verified in the TCGA-AML cohort. (g–i) TCGA-AML cohort showed that ICAM2 could not distinguish disease-free survival (DFS) in the intermediate-risk group, but the improved ELN-2017 stratification had a good predictive effect on DFS.